<p>ANI 製藥公司（NASDAQ:ANIP - 獲取免費報告）的股票在目前覆蓋該公司的九家評級機構中獲得了平均 “買入” 評級，Marketbeat.com 報道。一位投資分析師給予該股票 “持有” 評級，七位分析師給予 “買入” 評級，還有一位分析師給予 “強力買入” 評級。在過去一年中，更新了對該股票覆蓋的券商的平均十二個月目標價為 102.1429 美元。</p>
<p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
<p>幾位股票分析師對該公司發表了看法。Guggenheim 將 ANI 製藥的目標價從 114.00 美元上調至 115.00 美元，並在 11 月 10 日的研究報告中給予該公司 “買入” 評級。HC Wainwright 在 9 月 17 日的報告中將 ANI 製藥的目標價從 93.00 美元上調至 121.00 美元，並給予 “買入” 評級。巴克萊在週二的報告中開始覆蓋 ANI 製藥的股票，給予 “增持” 評級和 100.00 美元的目標價。華爾街禪在 8 月 16 日的研究報告中將 ANI 製藥的股票評級從 “買入” 上調至 “強力買入”。最後，Zacks Research 在 8 月 21 日的研究報告中將 ANI 製藥的股票評級從 “持有” 上調至 “強力買入”。</p>
<p><strong>查看我們最新的 ANIP 股票報告</strong></p>
<h2>ANI 製藥的內部買賣</h2>
<p>在 ANI 製藥的其他新聞中，副總裁 Meredith Cook 在 11 月 13 日的交易中出售了 400 股公司的股票。該股票以 87.27 美元的平均價格出售，總價值為 34,908.00 美元。交易後，副總裁持有 75,274 股公司的股票，價值約為 6,569,161.98 美元。此次交易使其持股減少了 0.53%。該交易已在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，董事 Renee P. Tannenbaum 在 12 月 5 日的交易中出售了 1,800 股公司的股票。該股票以 81.15 美元的平均價格出售，總價值為 146,070.00 美元。出售後，該董事直接持有 25,157 股公司的股票，價值約為 2,041,490.55 美元。這代表其持股減少了 6.68%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去的九十天裏，內部人士共出售了價值 2,378,393 美元的 26,979 股公司股票。公司內部人士持有 11.10% 的股票。</p>
<h2>ANI 製藥的機構交易</h2>
<p>對該股票的對沖基金最近增加或減少了其持股。查爾斯·施瓦布投資管理公司在第一季度將其在 ANI 製藥的持股增加了 0.9%。查爾斯·施瓦布投資管理公司現在擁有 238,377 股這家專業製藥公司的股票，價值 15,959,000 美元，此前在上個季度購買了 2,220 股。加拿大國家銀行 FI 在第一季度購買了 ANI 製藥的新頭寸，價值 79,000 美元。Connor Clark &amp; Lunn 投資管理有限公司在第一季度將其在 ANI 製藥的持股增加了 202.7%。Connor Clark &amp; Lunn 投資管理有限公司現在擁有 46,750 股這家專業製藥公司的股票，價值 3,130,000 美元，此前在上個季度購買了 31,308 股。景順有限公司在第一季度將其在 ANI 製藥的持股增加了 1.0%。景順有限公司現在擁有 199,567 股這家專業製藥公司的股票，價值 13,361,000 美元，此前在上個季度購買了 2,022 股。最後，Nuveen LLC 在第一季度購買了 ANI 製藥的新股份，價值 3,254,000 美元。機構投資者持有公司 76.05% 的股票。</p>
<h2>ANI 製藥股票上漲 0.1%</h2>
<p>NASDAQ:ANIP 週五開盤價為 82.13 美元。該公司的債務與股本比率為 1.20，流動比率為 2.58，速動比率為 2.04。ANI 製藥的股價在過去一年最低為 52.50 美元，最高為 99.50 美元。該公司的市值為 18.5 億美元，市盈率為 50.39，貝塔值為 0.48。該公司的 50 日移動平均線為 87.79 美元，200 日移動平均線為 80.39 美元。</p>
<p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近於 11 月 7 日公佈了季度財報。這家專業製藥公司報告的每股收益為 2.04 美元，超出市場共識預期的 1.74 美元，超出幅度為 0.30 美元。該公司本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。該公司本季度的收入較去年同期增長了 53.6%。去年同期，該公司每股收益為 1.34 美元。ANI 製藥已將其 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。作為一個整體，股票研究分析師預計 ANI 製藥在當前財年將發佈每股收益 3.86 美元。</p>
<h2>ANI 製藥公司簡介</h2>
<p>（獲取免費報告）</p>
<p>ANI 製藥公司是一家生物製藥公司，在美國和加拿大開發、生產和銷售品牌和仿製處方藥。該公司生產口服固體劑型；半固體、液體和外用劑型；受控物質；以及強效產品，並進行藥品的合同開發和生產。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>什麼是便士股票？全面指南</li>
<li>2026 年需避免的三隻最近被下調評級的股票</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>甲骨文股票遭重創：其人工智能管道為何可能推動 2026 年反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 ANI Pharmaceuticals 嗎？</h2>
<p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
<p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ANI制藥

<p>ANI 製藥公司（NASDAQ:ANIP）獲得了九位分析師的一致 “買入” 評級，目標價格為 102.14 美元。內部交易方面，副總裁梅雷迪斯·庫克和董事雷妮·P·坦嫩鮑姆出售了股份，而查爾斯·施瓦布和康納·克拉克與倫恩等機構投資者則增加了持股。該股票開盤價為 82.13 美元，市值為 18.5 億美元，市盈率為 50.39。最近的財報顯示每股收益為 2.04 美元，營收為 2.2781 億美元，超出預期</p>

<p>Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have earned an average rating of &#34;Buy&#34; from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $102.1429.</p>
<div class="lb-trans"><p>ANI 製藥公司（NASDAQ:ANIP - 獲取免費報告）的股票在目前覆蓋該公司的九家評級機構中獲得了平均 “買入” 評級，Marketbeat.com 報道。一位投資分析師給予該股票 “持有” 評級，七位分析師給予 “買入” 評級，還有一位分析師給予 “強力買入” 評級。在過去一年中，更新了對該股票覆蓋的券商的平均十二個月目標價為 102.1429 美元。</p>
</div><p>Get <strong>ANI Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>ANI 製藥</strong> 的提醒：</p>
</div><p>Several equities analysts have weighed in on the company. Guggenheim raised their price objective on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, November 10th. HC Wainwright increased their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, September 17th. Barclays initiated coverage on shares of ANI Pharmaceuticals in a report on Tuesday. They set an &#34;overweight&#34; rating and a $100.00 price target on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, August 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, August 21st.</p>
<div class="lb-trans"><p>幾位股票分析師對該公司發表了看法。Guggenheim 將 ANI 製藥的目標價從 114.00 美元上調至 115.00 美元，並在 11 月 10 日的研究報告中給予該公司 “買入” 評級。HC Wainwright 在 9 月 17 日的報告中將 ANI 製藥的目標價從 93.00 美元上調至 121.00 美元，並給予 “買入” 評級。巴克萊在週二的報告中開始覆蓋 ANI 製藥的股票，給予 “增持” 評級和 100.00 美元的目標價。華爾街禪在 8 月 16 日的研究報告中將 ANI 製藥的股票評級從 “買入” 上調至 “強力買入”。最後，Zacks Research 在 8 月 21 日的研究報告中將 ANI 製藥的股票評級從 “持有” 上調至 “強力買入”。</p>
</div><p><strong>Check Out Our Latest Stock Report on ANIP</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 ANIP 股票報告</strong></p>
</div><h2>Insider Buying and Selling at ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 製藥的內部買賣</h2>
</div><p>In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the business's stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the transaction, the vice president owned 75,274 shares of the company's stock, valued at approximately $6,569,161.98. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, Director Renee P. Tannenbaum sold 1,800 shares of the firm's stock in a transaction on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the sale, the director directly owned 25,157 shares of the company's stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 26,979 shares of company stock valued at $2,378,393 in the last ninety days. 11.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在 ANI 製藥的其他新聞中，副總裁 Meredith Cook 在 11 月 13 日的交易中出售了 400 股公司的股票。該股票以 87.27 美元的平均價格出售，總價值為 34,908.00 美元。交易後，副總裁持有 75,274 股公司的股票，價值約為 6,569,161.98 美元。此次交易使其持股減少了 0.53%。該交易已在提交給證券交易委員會的文件中披露，您可以通過此鏈接訪問。此外，董事 Renee P. Tannenbaum 在 12 月 5 日的交易中出售了 1,800 股公司的股票。該股票以 81.15 美元的平均價格出售，總價值為 146,070.00 美元。出售後，該董事直接持有 25,157 股公司的股票，價值約為 2,041,490.55 美元。這代表其持股減少了 6.68%。有關此次出售的更多細節可在官方 SEC 披露中找到。在過去的九十天裏，內部人士共出售了價值 2,378,393 美元的 26,979 股公司股票。公司內部人士持有 11.10% 的股票。</p>
</div><h2>Institutional Trading of ANI Pharmaceuticals</h2>
<div class="lb-trans"><h2>ANI 製藥的機構交易</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. increased its stake in shares of ANI Pharmaceuticals by 0.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after purchasing an additional 2,220 shares during the last quarter. National Bank of Canada FI bought a new position in ANI Pharmaceuticals during the first quarter valued at $79,000. Connor Clark &amp; Lunn Investment Management Ltd. increased its position in ANI Pharmaceuticals by 202.7% in the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 46,750 shares of the specialty pharmaceutical company's stock worth $3,130,000 after buying an additional 31,308 shares during the last quarter. Invesco Ltd. increased its position in ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after buying an additional 2,022 shares during the last quarter. Finally, Nuveen LLC bought a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $3,254,000. Institutional investors own 76.05% of the company's stock.</p>
<div class="lb-trans"><p>對該股票的對沖基金最近增加或減少了其持股。查爾斯·施瓦布投資管理公司在第一季度將其在 ANI 製藥的持股增加了 0.9%。查爾斯·施瓦布投資管理公司現在擁有 238,377 股這家專業製藥公司的股票，價值 15,959,000 美元，此前在上個季度購買了 2,220 股。加拿大國家銀行 FI 在第一季度購買了 ANI 製藥的新頭寸，價值 79,000 美元。Connor Clark &amp; Lunn 投資管理有限公司在第一季度將其在 ANI 製藥的持股增加了 202.7%。Connor Clark &amp; Lunn 投資管理有限公司現在擁有 46,750 股這家專業製藥公司的股票，價值 3,130,000 美元，此前在上個季度購買了 31,308 股。景順有限公司在第一季度將其在 ANI 製藥的持股增加了 1.0%。景順有限公司現在擁有 199,567 股這家專業製藥公司的股票，價值 13,361,000 美元，此前在上個季度購買了 2,022 股。最後，Nuveen LLC 在第一季度購買了 ANI 製藥的新股份，價值 3,254,000 美元。機構投資者持有公司 76.05% 的股票。</p>
</div><h2>ANI Pharmaceuticals Trading Up 0.1%</h2>
<div class="lb-trans"><h2>ANI 製藥股票上漲 0.1%</h2>
</div><p>NASDAQ:ANIP opened at $82.13 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The company has a market cap of $1.85 billion, a PE ratio of 50.39 and a beta of 0.48. The firm has a 50-day moving average of $87.79 and a 200-day moving average of $80.39.</p>
<div class="lb-trans"><p>NASDAQ:ANIP 週五開盤價為 82.13 美元。該公司的債務與股本比率為 1.20，流動比率為 2.58，速動比率為 2.04。ANI 製藥的股價在過去一年最低為 52.50 美元，最高為 99.50 美元。該公司的市值為 18.5 億美元，市盈率為 50.39，貝塔值為 0.48。該公司的 50 日移動平均線為 87.79 美元，200 日移動平均線為 80.39 美元。</p>
</div><p>ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. The business had revenue of $227.81 million for the quarter, compared to analysts' expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm's revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>ANI 製藥（NASDAQ:ANIP - 獲取免費報告）最近於 11 月 7 日公佈了季度財報。這家專業製藥公司報告的每股收益為 2.04 美元，超出市場共識預期的 1.74 美元，超出幅度為 0.30 美元。該公司本季度的收入為 2.2781 億美元，而分析師預期為 2.1192 億美元。ANI 製藥的淨利潤率為 4.91%，股本回報率為 26.73%。該公司本季度的收入較去年同期增長了 53.6%。去年同期，該公司每股收益為 1.34 美元。ANI 製藥已將其 2025 財年的指導目標設定為每股收益 7.370-7.640 美元。作為一個整體，股票研究分析師預計 ANI 製藥在當前財年將發佈每股收益 3.86 美元。</p>
</div><h2>ANI Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>ANI 製藥公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.</p>
<div class="lb-trans"><p>ANI 製藥公司是一家生物製藥公司，在美國和加拿大開發、生產和銷售品牌和仿製處方藥。該公司生產口服固體劑型；半固體、液體和外用劑型；受控物質；以及強效產品，並進行藥品的合同開發和生產。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than ANI Pharmaceuticals</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 ANI Pharmaceuticals</li>
<li>什麼是便士股票？全面指南</li>
<li>2026 年需避免的三隻最近被下調評級的股票</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>甲骨文股票遭重創：其人工智能管道為何可能推動 2026 年反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5JUA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ANIP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ANI Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 ANI Pharmaceuticals 嗎？</h2>
</div><p>Before you consider ANI Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ANI Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 ANI Pharmaceuticals 並不在名單上。</p>
</div><p>While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ANI Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ANI 製藥公司（NASDAQ:ANIP）被分析師一致評級為 “買入”